TGFB1 and idiopathic pulmonary fibrosis: Furthermore, the identification of TGF-β1 inhibitors through this platform highlights the potential for discovering novel therapeutic agents that can specifically target epithelial cell dysfunction in IPF, addressing a critical gap in current treatment strategies.